Bergamonte®

Why Bergamonte® and not others?

Bergamonte® is a standardized polyphenolic extract derived from Bergamot (Citrus bergamia) using patented extraction technology. Its high content of  citrus bioflavonoids helps to support cardiovascular health, as well as proper blood sugar metabolism.

 

Source: International Journal of Cardiology Dec 10, 2013: 170(2): 140-5

Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and Protein Kinase B phosphorylation in patients with hyperlipidemia

Micaela Gliozzi, Ross Walker, Saverio Muscoli, Cristiana Vitale, Santo Gratteri, Cristina Carresi, Vincenzo Musolino, Vanessa Russo, Elzbjeta Janda, Salvatore Ragusa, Antonio Aloe, Ernesto Palma, Carolina Muscoli, Franco Romeo and Vincenzo Mollace

Background: statins are the most commonly prescribed drugs to reduce cardiometabolic risk.

Beside the well-known efficacy of such compounds in both preventing and treating cardiometabolic disorders, some patients experience statin-induced side effects. We hypothesize that the use of natural bergamot-derived polyphenols may allow patients undergoing statin treatment to reduce effective doses while achieving target lipid values. The aim of the present study is to investigate the occurrence of an enhanced effect of bergamot-derived polyphenolic fraction (BPF) on rosuvastatin-induced hypolipidemic and vasoprotective response in patients with mixed hyperlipidemia.

Methods: a prospective, open-label, parallel group, placebo-controlled study on 77 patients with elevated serum LDL-C and triglycerides was designed. Patients were randomly assigned to a control group receiving placebo (n= 15), two groups receiving orally administered rosuvastatin (10 and 20 mg/daily for 30 days; n= 16 for each group), a group receiving BPF alone orally (1000 mg/daily for 30 days; n=15) and a group receiving BPF (1000 mg/daily given orally) plus rosuvastatin (10 mg/daily for 30 days; n=15).

Results: both doses of rosuvastatin and BPF reduced total cholesterol, LDL-C, the LDL-C/ HDL-C ratio and urinary mevalonate in hyperlipidemic patients, compared to the control group. The cholesterol lowering effect was accompanied by reductions of malondialdehyde, oxyLDL receptor LOX-1 and phosphoPKB, which are all biomarkers of oxidative vascular damage, in peripheral polymorphonuclear cells.

Conclusions: The addition of BPF to rosuvastatin significantly enhanced rosuvastatin-induced effect on serum lipemic profile compared to rosuvastatin alone. This lipid-lowering effect was associated with significant reductions of biomarkers used for detecting oxidative vascular damage, suggesting a multi-action enhanced potential for BPF in patients on statin therapy.

 

Click here to get our published research studies by registering with us as a
Certified Health Provider

 

This page is for education purpose only.

 

 Disclaimer